• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

    6/5/24 8:07:39 AM ET
    $AMC
    $ANNX
    $CMPS
    $DLTR
    Movies/Entertainment
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMC alert in real time by email

    U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday.

    Shares of DouYu International Holdings Limited (NASDAQ:DOYU) fell in today's pre-market trading following first-quarter results.

    DouYu International reported a fiscal first-quarter 2024 revenue decline of 29.9% to $144 million year-on-year, missing the analyst consensus estimate of $184 million. The Chinese game-centric live streaming platform's adjusted earnings per ADS loss of 37 cents compared to $1.10 Y/Y, according to data from Benzinga Pro.

    DouYu International shares fell 4.2% to $9.70 in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • COMPASS Pathways plc (NASDAQ:CMPS) shares dipped 16.6% to $6.40 in pre-market trading.
    • Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares declined 15.2% to $7.00 in pre-market trading after declining 5% on Tuesday.
    • Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) fell 12% to $215.00 in pre-market trading.
    • Annexon, Inc. (NASDAQ:ANNX) shares declined 11.5% to $5.30 in pre-market trading after the company announced a proposed public offering of common stock.
    • Integral Ad Science Holding Corp (NASDAQ:IAS) shares fell 4.5% to $8.74 in pre-market trading.
    • Dollar Tree, Inc. (NASDAQ:DLTR) shares fell 2.4% to $117.46 in pre-market trading after the company reported first-quarter earnings and announced a review of strategic alternatives for its Family Dollar business.
    • AMC Entertainment Holdings, Inc (NYSE:AMC) shares declined 2.5% to $4.67 in pre-market trading.

    Now Read This: Dollar Tree, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Wednesday

    Don't forget to check out our premarket coverage here

    Get the next $AMC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMC
    $ANNX
    $CMPS
    $DLTR

    CompanyDatePrice TargetRatingAnalyst
    Dollar Tree Inc.
    $DLTR
    2/27/2026$132.00Buy → Neutral
    Citigroup
    Dollar Tree Inc.
    $DLTR
    2/17/2026$165.00Neutral → Buy
    Rothschild & Co Redburn
    Dollar Tree Inc.
    $DLTR
    2/13/2026$95.00Market Perform → Underperform
    BMO Capital Markets
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/28/2026$964.00Overweight
    Barclays
    Dollar Tree Inc.
    $DLTR
    1/21/2026Neutral → Underperform
    BNP Paribas Exane
    Madrigal Pharmaceuticals Inc.
    $MDGL
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    COMPASS Pathways Plc
    $CMPS
    12/10/2025$15.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $AMC
    $ANNX
    $CMPS
    $DLTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 18, 2024 - FDA Roundup: June 18, 2024

    For Immediate Release: June 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for input about patient safety associated with certain medical software functions excluded from the medical device definition. This input will help the FDA develop the 2024 report on the risks and benefits to health of non-devic

    6/18/24 3:16:28 PM ET
    $DLTR
    $AMGN
    Department/Specialty Retail Stores
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

    Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

    3/14/24 3:35:50 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMC
    $ANNX
    $CMPS
    $DLTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AMC Entertainment Delivers Best Ever Global Revenue Mark for a 5-Day Easter Weekend, Led by THE SUPER MARIO GALAXY MOVIE, Strong Merchandise Sales, and Solid Performances by Other Titles

    Led by a media-reported global box office debut of $372 million for THE SUPER MARIO GALAXY MOVIE, AMC Entertainment posted its largest combined global admissions and food & beverage revenue for a 5-day Easter weekend in the Company's 106-year history More than 6.0 million moviegoers attended AMC Theatres in the United States or ODEON Cinemas internationally from Wednesday, April 1 through Sunday, April 5; this was also AMC's highest global attendance for Wednesday through Sunday in 2026 AMC's merchandise program for THE SUPER MARIO GALAXY MOVIE was a major hit with moviegoers and ranks as AMC's second-best selling and second-highest grossing merchandise program of all time, behind only

    4/6/26 8:20:00 AM ET
    $AMC
    Movies/Entertainment
    Consumer Discretionary

    Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); U.S./European FORWARD Study Data Expected to Support Planned BLA Submission in 2026 ANX1502 Advancing as First Oral C1 Inhibitor for Autoimmune Disease; Proof-of-Concept (POC) Data Anticipated in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $238.3 Million as of December 31, 2025, and Anticipated Runway into Second Half 2027 BRISBANE, Calif., March 30,

    3/30/26 4:01:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DouYu International Holdings Limited Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results

    WUHAN, China, March 25, 2026 /PRNewswire/ -- DouYu International Holdings Limited ("DouYu" or the "Company") (NASDAQ:DOYU), a leading game-centric live streaming platform in China and a pioneer in the eSports value chain, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal net revenues in the fourth quarter of 2025 were RMB918.8 million (US$131.4 million), compared with RMB1,136.0 million in the same period of 2024.Gross profit in the fourth quarter of 2025 was RMB118.0 million (US$16.9 million), compared with RMB69.8 million in the same period of 2024. Income from operations in the fourth

    3/25/26 5:00:00 AM ET
    $DOYU
    Computer Software: Programming Data Processing
    Technology

    $AMC
    $ANNX
    $CMPS
    $DLTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dollar Tree downgraded by Citigroup with a new price target

    Citigroup downgraded Dollar Tree from Buy to Neutral and set a new price target of $132.00

    2/27/26 8:27:18 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Dollar Tree upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Dollar Tree from Neutral to Buy and set a new price target of $165.00

    2/17/26 8:01:44 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    Dollar Tree downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Dollar Tree from Market Perform to Underperform and set a new price target of $95.00

    2/13/26 8:27:52 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    $AMC
    $ANNX
    $CMPS
    $DLTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMC
    $ANNX
    $CMPS
    $DLTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Maheshwari Aditya

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    4/3/26 6:21:58 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form 4 filed by Glendinning Stewart

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    4/3/26 6:15:40 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form 4 filed by Aflatooni Robert

    4 - DOLLAR TREE, INC. (0000935703) (Issuer)

    4/3/26 6:10:41 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    $AMC
    $ANNX
    $CMPS
    $DLTR
    SEC Filings

    View All

    AMC Entertainment Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Filer)

    4/1/26 4:55:42 PM ET
    $AMC
    Movies/Entertainment
    Consumer Discretionary

    SEC Form S-3ASR filed by Annexon Inc.

    S-3ASR - Annexon, Inc. (0001528115) (Filer)

    3/30/26 7:42:53 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Annexon Inc.

    10-K - Annexon, Inc. (0001528115) (Filer)

    3/30/26 5:30:31 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMC
    $ANNX
    $CMPS
    $DLTR
    Financials

    Live finance-specific insights

    View All

    Dollar Tree, Inc. Reports Fourth Quarter and Full Year 2025 Results

    Q4 comparable store net sales growth of 5.0% Q4 diluted EPS from continuing operations of $2.56 FY25 net sales growth of 10% and comparable store net sales growth of 5.3% FY25 diluted EPS from continuing operations of $5.94 Q4 adjusted diluted EPS increased 21% to $2.56 FY25 adjusted diluted EPS increased 13% to $5.75 Returned $1.548 billion to shareholders through share repurchases in fiscal 2025 Quarter to date share repurchases are $193 million Introducing fiscal 2026 outlook of comparable store net sales growth of 3% to 4% and adjusted EPS from continuing operations of $6.50 to $6.90 Q1 fiscal 2026 outlook of 3% to 4% comparable store net sales growth and adj

    3/16/26 6:30:00 AM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    National CineMedia, Inc. Reports Results for Fiscal Fourth Quarter and Full Year 2025

    Fourth quarter operating income increases year-over-year and fourth quarter adjusted OIBDA exceeds guidance Fourth quarter revenue growth of 8% outpaced attendance as NCM attracted greater advertiser demand National CineMedia, Inc. (NASDAQ:NCMI) (the "Company" or "NCM"), the managing member of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising platform in the U.S., announced today its consolidated results for the fiscal fourth quarter and year ended January 1, 2026. "NCM expanded fourth quarter revenue by 8% year-over-year, demonstrating the returns from our continued investment in our platform over the course of the year," said Tom Lesinski, Chief Execu

    2/26/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    Dollar Tree, Inc. to Host Fourth Quarter Earnings Conference Call

    Dollar Tree, Inc. (NASDAQ:DLTR), will report financial results for the fourth quarter 2025 ended January 31, 2026, before the stock market opens on Monday, March 16, 2026, followed by a conference call for investors and analysts at 8 a.m. ET. Chief Executive Officer Mike Creedon and Chief Financial Officer Stewart Glendinning will discuss the company's results and lead a question-and-answer session. WHEN: Monday, March 16, 2026 8 a.m. Eastern Time   DIAL-IN: Please dial (877) 407-3943 or (201) 689-8855 at least 10 minutes prior to the scheduled start time.   WEBCAST: Available on the investor relations section of the company's websi

    2/23/26 4:00:00 PM ET
    $DLTR
    Department/Specialty Retail Stores
    Consumer Discretionary

    $AMC
    $ANNX
    $CMPS
    $DLTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 6:46:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integral Ad Science Holding Corp.

    SC 13G/A - INTEGRAL AD SCIENCE HOLDING CORP. (0001842718) (Subject)

    11/14/24 6:19:26 PM ET
    $IAS
    Computer Software: Programming Data Processing
    Technology

    $AMC
    $ANNX
    $CMPS
    $DLTR
    Leadership Updates

    Live Leadership Updates

    View All

    Tim Johnson Nominated to Join Amaero Board

    MCDONALD, Tenn., March 10, 2026 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTC:AMROF) ("Amaero" or the "Company"), a leading U.S. domestic producer of high-value refractory and titanium alloy powders for additive and advanced manufacturing of components utilized by the defense, space, and aviation industries, is pleased to announce that Tim "TJ" Johnson has been nominated to join Amaero's Board as a Non-Executive Director, subject to satisfying the requisite regulatory requirements. Upon joining the Board as a Non-Executive Director, it is anticipated that he will assume the responsibilities of Chairman of the Audit and Risk Committee. Mr. Johnson is an experienced corporate board member

    3/10/26 8:00:00 AM ET
    $DLTR
    $DRVN
    $EAT
    Department/Specialty Retail Stores
    Consumer Discretionary
    Automotive Aftermarket
    Restaurants

    Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH

    SUZHOU, China and MÖLNDAL, Sweden, Feb. 11, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (HKEX: 06938) ("Ribo") and its subsidiary Ribocure Pharmaceuticals AB ("Ribocure") today announced that they have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will utilize Ribo's validated liver targeting siRNA GalSTARTM platform to develop novel treatm

    2/11/26 6:25:00 AM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAIKA Partners With Fathom Entertainment for Domestic Distribution and FilmNation Entertainment for International Sales on Wildwood

    Confirms October 23, 2026 U.S. Release Date LAIKA, the studio behind Coraline and ParaNorman, announced today that it has partnered with Fathom Entertainment for U.S. theatrical distribution and FilmNation Entertainment for international sales on its upcoming stop-motion feature film Wildwood. The film will open in theaters nationwide on October 23, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938376/en/LAIKA Names Fathom Entertainment as US Distributor and FilmNation Entertainment for International Sales for "Wildwood" coming October 23, 2026 The announcement reflects a new phase for LAIKA, as the studio expands

    1/20/26 11:15:00 AM ET
    $AMC
    $CNK
    Movies/Entertainment
    Consumer Discretionary